Financing driven by psychedelic investment fund Negev Capital and leading functional mushroom manufacturer Nammex VANCOUVER, BC, June 30, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, is pleased to announce that it intends to complete, subject to regulatory approval…


Previous articleatai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer
Next articlePT333 – Miriam Volat, MS & T. Cody Swift, MFT – Conservation, Peyote, and Indigenous Biocultural Survival